Evidencing the presence of merkel cell polyomavirus in papillary thyroid cancer

Ghanghareh, Monir; Amroabadi, Jalal Mosayebi; Tavangar, Seyed Mohammad; Irani, Shiva; Sakhaee, Fatemeh; Jajin, Morteza Ghazanfari; Vaziri, Farzam; Siadat, Seyed Davar; Fateh, Abolfazl

doi:10.1038/s41598-021-01055-2

Cited by 6 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In techniques such as next-generation sequencing, mass spectrometry, and quantitative real-time PCR, FBS is recommended. As a result, these samples are considered the gold standard for DNA and RNA analysis [ 4 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…In this case, viral genomes or tiny viral fragments may be discovered in malignant tumors or tumor precursors. Ironically, both transformational activities and hit-and-run processes have been investigated in non-transforming viruses that appear to be unrelated to human cancer [ 4 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

“…JCPyV DNA positivity alone is insufficient for determining the etiology of JCPyV as another infectious agent linked to PTC [ 4 ]. Several studies have demonstrated that polyomaviruses LT -Ag expression is needed for the carcinogenesis [ 4 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Deparaffinization was performed, as previously described [ 4 ]. After tissue deparaffinization, genomic DNA from FBS and PEBS was extracted using a High Pure FFPET DNA Isolation Kit (Roche Diagnostics Deutschland GmbH, Mannheim, Germany), according to the manufacturer’s instructions .…”

Section: Methodsmentioning

confidence: 99%

“…However, it should be noted that most patients have no risk factor at all [ 2 ]. The correlation of TC with human parvovirus B19, BK polyomavirus (BKPyV), human herpes simplex virus, Epstein–Barr viruses, hepatitis C virus, and Merkel cell polyomavirus (MCPyV) has been evaluated and confirmed by several studies [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Traces of JC polyomavirus in papillary thyroid cancer: a comprehensive study in Iran

Karimi

Tarharoudi

Kianmehr

et al. 2022

Virol J

Self Cite

View full text Add to dashboard Cite

Background JC polyomavirus (JCPyV) is known to induce solid tumors such as astrocytomas, glioblastomas, and neuroblastomas in experimental animals, and recent studies have shown that the virus may be correlated with carcinogenesis. This study aimed to evaluate the impact of JCPyV on the progression of papillary thyroid cancer (PTC). Methods A total of 1057 samples, including 645 paraffin-embedded PTC biopsy samples (PEBS) and 412 fresh biopsy samples (FBS), and 1057 adjacent non-cancerous samples were evaluated for the presence of JCPyV DNA and RNA. Results We observed that 10.8% (114/1057) samples, including 17.5% (72/412) FBS and 6.5% (42/645) PEBS were positive for the JCPyV DNA. Among the JCPyV-positive samples, the mean JCPyV copy number was lower in patients with PEBS (0.3 × 10–4 ± 0.1 × 10–4 copies/cell) compared to FBS (1.8 × 10–1 ± 0.4 × 10–1 copies/cell) and non-PTC normal samples (0.2 × 10–5 ± 0.01 × 10–5 copies/cell), with a statistically significant difference (P < 0.001). The LT-Ag RNA expression was lower in PEBS than in FBS, while no VP1 gene transcript expression was found. Conclusions Although our results confirmed the presence of JCPyV in some Iranian patients with PTC, more research is needed to verify these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Traces of JC polyomavirus in papillary thyroid cancer: a comprehensive study in Iran

Karimi

Tarharoudi

Kianmehr

et al. 2022

Virol J

Self Cite

View full text Add to dashboard Cite

show abstract

Risk of Multiple Primary Cancers in Patients With Merkel Cell Carcinoma

Eid,

Maloney,

Cai

et al. 2023

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceThe risk of subsequent primary cancers after a diagnosis of cutaneous Merkel cell carcinoma (MCC) is not well established.ObjectiveTo evaluate the risk of subsequent primary cancers after the diagnosis of a first primary cutaneous MCC.Design, Setting, and ParticipantsThis cohort study analyzed data from 17 registries of the Surveillance, Epidemiology, and End Results (SEER) Program from January 1, 2000, to December 31, 2019. In all, 6146 patients diagnosed with a first primary cutaneous MCC were identified.Main Outcomes and MeasuresThe primary outcome was the relative and absolute risks of subsequent primary cancers after the diagnosis of a first primary MCC, which were calculated using the standardized incidence ratio (SIR; ratio of observed to expected cases of subsequent cancer) and the excess risk (difference between observed and expected cases of subsequent cancer divided by the person-years at risk), respectively. Data were analyzed between January 1, 2000, and December 31, 2019.ResultsOf 6146 patients with a first primary MCC diagnosed at a median (IQR) age of 76 (66-83) years, 3713 (60.4%) were men, and the predominant race and ethnicity was non-Hispanic White (5491 individuals [89.3%]). Of these patients, 725 (11.8%) developed subsequent primary cancers, with an SIR of 1.28 (95% CI, 1.19-1.38) and excess risk of 57.25 per 10 000 person-years. For solid tumors after MCC, risk was elevated for cutaneous melanoma (SIR, 2.36 [95% CI, 1.85-2.97]; excess risk, 15.27 per 10 000 person-years) and papillary thyroid carcinoma (SIR, 5.26 [95% CI, 3.25-8.04]; excess risk, 6.16 per 10 000 person-years). For hematologic cancers after MCC, risk was increased for non-Hodgkin lymphoma (SIR, 2.62 [95% CI, 2.04-3.32]; excess risk, 15.48 per 10 000 person-years).Conclusions and RelevanceThis cohort study found that patients with MCC had an increased risk of subsequently developing solid and hematologic cancers. This increased risk may be associated with increased surveillance, treatment-related factors, or shared etiologies of the other cancers with MCC. Further studies exploring possible common etiological factors shared between MCC and other primary cancers are warranted.

show abstract

BK polyomavirus in Iranian patients with papillary thyroid cancer: Is it a major future challenge?

Tarharoudi

Sari

Sakhaee

et al. 2022

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

BK polyomavirus (BKPyV) is a well-known cause of nephropathy in renal transplant recipients. It has recently received much attention from researchers as a major predisposing factor for various cancers. This study aimed to investigate how BKPyV affected the advancement of papillary thyroid carcinoma (PTC). A total of 1057 samples were tested for BKPyV DNA and RNA, comprising 645 paraffin-embedded PTC biopsy samples (PEBS), 412 fresh biopsy samples (FBS), and 1057 adjacent noncancerous samples. The BKPyV DNA was found in 511 (48.3%) of the specimens, including 347 (84.2%) FBS and 164 (25.4%) PEBS. The mean BKPyV copy number was significantly lower in patients with PEBS (0.5 × 10 −4 ± 0.1 × 10 −4 copies/cell) than in FBS (1.3 × 10 −1 ± 0.2 × 10 −1 copies/cell) and non-PTC normal samples (0.3 × 10 −5 ± 0.04 × 10 −5 copies/cell). The PEBS had lower LT-Ag RNA expression than FBS, and no VP1 gene transcript expression was detected. In conclusion, although our findings indicated the presence of BKPyV in some Iranian PTC patients, more research is needed to corroborate these findings.

show abstract

Evidencing the presence of merkel cell polyomavirus in papillary thyroid cancer

Cited by 6 publications

References 31 publications

Traces of JC polyomavirus in papillary thyroid cancer: a comprehensive study in Iran

Traces of JC polyomavirus in papillary thyroid cancer: a comprehensive study in Iran

Risk of Multiple Primary Cancers in Patients With Merkel Cell Carcinoma

BK polyomavirus in Iranian patients with papillary thyroid cancer: Is it a major future challenge?

Contact Info

Product

Resources

About